EC Number   |
Reference |
|---|
   6.1.1.14 | - |
133 |
| 6.1.1.14 | alpha-subunit the enzyme and its complexes with ATP, and ATP and glycine, sitting drop vapor diffusion method, using 0.1 M Bis-Tris propane:NaOH pH 7.0 and 0.7 M magnesium formate (complex with glycine), or 0.1 M Tris-HCl pH 8.5 and 0.3 M magnesium chloride (complex with ATP), or 0.1 M Na2HPO4-citrate acid pH 4.2, 0.2 M lithium sulfate and 20% (w/v) PEG 1000 (complex with ATP and glycine) |
728217 |
| 6.1.1.14 | apo form of full-length E71G mutant and tRNA-bound mutant complex E71G/C157R, vapor diffusion method, using 13-15% (w/v) PEG 6000, 0.1 M sodium citrate buffer (pH 5.5), and 0.1 M NaCl |
745358 |
| 6.1.1.14 | at 2.75 A resolution |
141 |
| 6.1.1.14 | purified His-tagged wild-type and S581L mutant enzymes, sitting drop vapour diffusion nanocrystallization method, mutant S581L GlyRS from 20% PEG 3350, 0.2 M Na2SO4, 0.1 M Bis-Tris propane, pH 6.5, wild-type GlyRS from 20% PEG 3350, 0.2M sodium bromide, 0.1 M bis-Tris propane pH 8.5, X-ray diffraction structure determination and anaylsis at 2.8A and 3.1 A resolution, respectively |
673686 |
| 6.1.1.14 | purified recombinant soluble enzyme, hanging drop vapour diffusion method, 0.001 ml of 8 mg/ml protein in 10 mM HEPES, pH 7.0, with 20 mM NaCl is mixed with 0.001 ml of reservoir solution containing 10% PEG 6000, 0.1 HEPES pH 6.5, 0.01 Tris-HCl, pH 8.5, 0.5 NaCl and 0.1 magnesium acetate at room temperature, 2 days, X-ray diffraction structure determination and analysis at 3.0 A resolution |
671098 |
| 6.1.1.14 | vapor diffusion method, using 0.2% (w/v) 4-diaminobutane, 0.2% (w/v) cystamine dihydrochloride, 0.2% (w/v) diloxanide furoate, 0.2% (w/v) sarcosine, 0.2% (w/v) spermine, and 0.02 M HEPES sodium (pH 6.8) at a 2:1:1 ratio |
745302 |
